Johnson & Johnson (JNJ/NYSE/S&P500)
06 September 2017, 12:07
| Scenario | |
|---|---|
| Timeframe | Intraday |
| Recommendation | SELL STOP |
| Entry Point | 129.70 |
| Take Profit | 129.00, 128.25, 127.50 |
| Stop Loss | 130.60 |
| Key Levels | 129.00, 129.80, 131.00, 131.80, 132.50 |
| Alternative scenario | |
|---|---|
| Recommendation | BUY STOP |
| Entry Point | 131.10 |
| Take Profit | 132.50, 133.00 |
| Stop Loss | 130.25 |
| Key Levels | 129.00, 129.80, 131.00, 131.80, 132.50 |
Industry: medicines producer
Current trend
In the recent renewed health care sector IHS Markit report the rating of Johnson & Johnson was renewed from neutral to positive, which brings the pharmaceutics giant into leaders against the competitors in the sector.
Johnson & Johnson jointly with pharmaceutical company Geron are developing Imetelstat – the medicine for curing myelofibrosis symptoms, which can take from the leader of the segment Jakafi by Merck around 1.1 billion USD of the year sales, beginning with 2019.
During the last week Johnson & Johnson stocks decreased by 1.40% against the fall of S&P 500 index by 0.53%.
The comparative analysis between the indicators of the company and its competitors suggests the neutrality of its share prices.
Key levels
The “bearish” moods prevail. Yesterday the price decreased by 0.86%. The issuer has reached the key support level of 129.80. The round level of 131.00 is the “mirror” resistance. The indicators’ signals are controversial, but it’s better to open positions according to the current trend.
Support levels: 129.80, 129.00.
Resistance levels: 131.00, 131.80, 132.50.
Trading tips
If the price is set below the level of 129.80, find entering point to open short positions. Closing profitable positions is possible at the levels of 129.00, 128.25, 127.50. Stop loss is 130.60.
Technical correction of stock is not excluded. If the price is set above the round level of 131.00, it’s better to open long positions with the targets at 132.50–133.00. Stop loss is 130.25.
Implementation period: 3 days.
Current trend
In the recent renewed health care sector IHS Markit report the rating of Johnson & Johnson was renewed from neutral to positive, which brings the pharmaceutics giant into leaders against the competitors in the sector.
Johnson & Johnson jointly with pharmaceutical company Geron are developing Imetelstat – the medicine for curing myelofibrosis symptoms, which can take from the leader of the segment Jakafi by Merck around 1.1 billion USD of the year sales, beginning with 2019.
During the last week Johnson & Johnson stocks decreased by 1.40% against the fall of S&P 500 index by 0.53%.
The comparative analysis between the indicators of the company and its competitors suggests the neutrality of its share prices.
Key levels
The “bearish” moods prevail. Yesterday the price decreased by 0.86%. The issuer has reached the key support level of 129.80. The round level of 131.00 is the “mirror” resistance. The indicators’ signals are controversial, but it’s better to open positions according to the current trend.
Support levels: 129.80, 129.00.
Resistance levels: 131.00, 131.80, 132.50.
Trading tips
If the price is set below the level of 129.80, find entering point to open short positions. Closing profitable positions is possible at the levels of 129.00, 128.25, 127.50. Stop loss is 130.60.
Technical correction of stock is not excluded. If the price is set above the round level of 131.00, it’s better to open long positions with the targets at 132.50–133.00. Stop loss is 130.25.
Implementation period: 3 days.
No comments:
Write comments